Loading stock data…
STE
$202.81-4.65 (-2.24%)
Market OpenUpdated 2:40 PM EDT
STERIS plc provides infection prevention products and services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
STERIS plc in the Healthcare sector is trading at $202.81. The stock is currently near its 52-week low of $195.14, remaining 16.2% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why STE maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$202.81
Potential Downside
36.4%
Whystock Fair Value$129.02
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$279.29+37.7%
Range$231.00 – $300.00
Fundamentals
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assuran...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.14
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Strong income play. Yield provides a meaningful total return floor.
110.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.04%
Volume
Today's trading volume
494,046
Recent News
How STERIS' (STE) New Diagnostics-Focused Director and Dividend Move Could Shape Investor Perceptions
On May 5, 2026, STERIS plc appointed bioMérieux CEO Pierre Boulud to its Board of Directors and affirmed a US$0.6300 quarterly dividend payable on June 26, 2026. Boulud’s background in global diagnostics and biopharmaceutical markets adds sector-specific expertise and international experience to STERIS’s boardroom decision-making. We’ll now examine how adding Pierre Boulud’s diagnostics-focused experience to the board could influence STERIS’s broader investment narrative. Outshine the...
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +52.94% and +6.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, STERIS’s stock price fell to $214.47. Shareholders have lost 11.3% of their capital, which is disappointing considering the S&P 500 has climbed by 6.4%. This may have investors wondering how to approach the situation.
STERIS' Q4 Earnings on Deck: What's in Store for the Stock?
STE heads into Q4 earnings with steady estimates and strong segment growth expectations - will momentum across healthcare and life sciences continue?